Search hospitals > Minnesota > Minneapolis
University of Minnesota/Masonic Cancer Center
Claim this profileMinneapolis, Minnesota 55455
Global Leader in Leukemia
Global Leader in Tumors
Conducts research for Lymphoma
Conducts research for Cancer
Conducts research for Acute Myeloid Leukemia
723 reported clinical trials
36 medical researchers
Summary
University of Minnesota/Masonic Cancer Center is a medical facility located in Minneapolis, Minnesota. This center is recognized for care of Leukemia, Tumors, Lymphoma, Cancer, Acute Myeloid Leukemia and other specialties. University of Minnesota/Masonic Cancer Center is involved with conducting 723 clinical trials across 682 conditions. There are 36 research doctors associated with this hospital, such as Emily Greengard, Manish Patel, Christopher Moertel, and Peter M. Gordon.Area of expertise
1Leukemia
Global LeaderStage II
Stage I
Stage III
2Tumors
Global LeaderStage IV
Stage I
Stage II
Top PIs
Emily GreengardUniversity of Minnesota/Masonic Cancer Center4 years of reported clinical research
Expert in Tumors
Expert in Neuroblastoma
45 reported clinical trials
71 drugs studied
Manish PatelFlorida Cancer Specialists3 years of reported clinical research
Expert in Solid Tumors
Studies Tumors
30 reported clinical trials
48 drugs studied
Christopher MoertelUniversity of Minnesota/Masonic Cancer Center4 years of reported clinical research
Studies Neurofibromatosis
Studies Brain Tumor
15 reported clinical trials
24 drugs studied
Peter M. GordonUniversity of Minnesota/Masonic Cancer Center4 years of reported clinical research
Studies Leukemia
Studies Lymphoblastic Leukemia-Lymphoma
13 reported clinical trials
39 drugs studied
Clinical Trials running at University of Minnesota/Masonic Cancer Center
Breast Cancer
Acute Myeloid Leukemia
Cancer
Lymphoma
Leukemia
Non-Hodgkin's Lymphoma
Tumors
Osteosarcoma
Brain Tumor
Solid Tumors
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
[225Ac]-FPI-1434
for Cancer
This is a first-in-human Phase 1/2, non-randomized, multi-centre, open-label clinical study designed to investigate safety, tolerability, PK, and preliminary anti-tumour activity of \[225Ac\]-FPI-1434 (radioimmuno-therapeutic agent) in patients with solid tumours that demonstrate uptake of \[111In\]-FPI-1547 (radioimmuno-imaging agent), and to establish the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of repeat doses of \[225Ac\]-FPI-1434 Injection in patients with solid tumours that demonstrate uptake of \[111In\]-FPI-1547 (radioimmuno-imaging agent).
Recruiting1 award Phase 1 & 211 criteria
Physical Therapy
for Breast Cancer
Phase 1: The investigators will conduct a prospective study to quantify the association between axillary web syndrome (AWS) and metastatic disease and chronic morbidities such as lymphedema, shoulder dysfunction, and pain comparing women (i) with AWS and (ii) without AWS in two cohorts of women. (n=200) Phase 2: This is a randomized controlled trial to 1) quantify the effects of (i) physical therapy compared to (ii) a control group in individuals with AWS following breast cancer surgery related to physical activity and physical impairments such as lymphedema, shoulder motion, function, and pain (n=44, 22 in each group). Funding to progress to Phase 2 of this trial has been obtained. It is anticipated 120 subjects participating in Phase 1 will be screened for eligibility for Phase 2 (separate consent and eligibility from Phase 1).
Recruiting1 award N/A4 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at University of Minnesota/Masonic Cancer Center?
University of Minnesota/Masonic Cancer Center is a medical facility located in Minneapolis, Minnesota. This center is recognized for care of Leukemia, Tumors, Lymphoma, Cancer, Acute Myeloid Leukemia and other specialties. University of Minnesota/Masonic Cancer Center is involved with conducting 723 clinical trials across 682 conditions. There are 36 research doctors associated with this hospital, such as Emily Greengard, Manish Patel, Christopher Moertel, and Peter M. Gordon.
Where is University of Minnesota/Masonic Cancer Center located?
**Masonic Cancer Center, University of Minnesota Health Clinics and Surgery Center**
- **Location:** 425 E River Pkwy, Minneapolis, MN 55455.
- **Directions:** From I-35W south, take Highway 280 south to I-94W, then continue to Huron Boulevard.
- **City:** Minneapolis, MN.
Who should I call to ask about financial aid or insurance network?
The University of Minnesota/Masonic Cancer Center offers several contact options for financial assistance and insurance queries:
- For general payment inquiries, contact the Community-University Health Care Center (CUHCC) at 612-301-3433.
- For cancer-related insurance guidance, reach out to the Masonic Cancer Clinic's Cancer Information Nurse Line at 612-624-2620.
- To schedule appointments, call 612-676-4200, and for hematology and oncology services referrals, contact M Health Fairview Cancer Care at 855-486-7226.
What insurance does University of Minnesota/Masonic Cancer Center accept?
The University of Minnesota Physicians encourage patients to understand their insurance coverage, benefits, and out-of-pocket costs before visiting. For detailed information on accepted insurance plans, contact the University of Minnesota/Masonic Cancer Center directly or visit their official website.
What awards or recognition has University of Minnesota/Masonic Cancer Center received?
The Masonic Cancer Center at the University of Minnesota, located in Minneapolis, Minnesota, is a National Cancer Institute-designated comprehensive cancer center since 1998. It is recognized for its outstanding research and care. The center has also been awarded a $5.1 million grant by the National Institute of Environmental Health Sciences to research the impact of environmental factors on cancer.